Indolent B-Cell NHL, CD20+, low tumor burden
Item
patient with cd20 positive low tumor burden indolent b-cell non- hodgkin's lymphoma.
boolean
C1334170 (UMLS CUI [1,1])
C0079731 (UMLS CUI [1,2])
C3888518 (UMLS CUI [1,3])
C1449699 (UMLS CUI [1,4])
C0205251 (UMLS CUI [1,5])
Measurable disease Quantity
Item
patient with at least one measurable lesion.
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
ECOG performace status
Item
patient with ecog performance status 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Recent radiotherapy | prior radiotherapy recovery lacking
Item
patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy.
boolean
C1522449 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0279134 (UMLS CUI [2,1])
C2004454 (UMLS CUI [2,2])
C0332268 (UMLS CUI [2,3])
Recent immunotherapy, chemotherapy, antibodies, experimental treatment | prior therapy recovery lacking
Item
patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy.
boolean
C0021083 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C0332185 (UMLS CUI [2,2])
C3542957 (UMLS CUI [3,1])
C0332185 (UMLS CUI [3,2])
C0304229 (UMLS CUI [4,1])
C0332185 (UMLS CUI [4,2])
C1514463 (UMLS CUI [5,1])
C2004454 (UMLS CUI [5,2])
C0332268 (UMLS CUI [5,3])
Prior therapy with monoclonal antibodies | except for rituximab
Item
patient who has mab therapy other than rituximab as prior line of therapy.
boolean
C1514463 (UMLS CUI [1,1])
C0003250 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0393022 (UMLS CUI [2,2])
Uncontrolled infectious disease | viral, bacterial or fungal infection
Item
patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal).
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0042769 (UMLS CUI [2])
C0004623 (UMLS CUI [3])
C0026946 (UMLS CUI [4])
Cancer Other | Exception Carcinoma in situ of uterine cervix Treated | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated
Item
patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer.
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0851140 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
Clinical Trial Eligibility Criteria; Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])